Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Change in Account Payables (2020 - 2024)

Relay Therapeutics (RLAY) has disclosed Change in Account Payables for 5 consecutive years, with -$4.3 million as the latest value for Q3 2024.

  • On a quarterly basis, Change in Account Payables fell 251.88% to -$4.3 million in Q3 2024 year-over-year; TTM through Sep 2024 was -$6.4 million, a 228.7% decrease, with the full-year FY2023 number at -$2.4 million, down 220.36% from a year prior.
  • Change in Account Payables was -$4.3 million for Q3 2024 at Relay Therapeutics, down from $3.2 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $4.6 million in Q3 2022 to a low of -$5.4 million in Q4 2023.
  • A 5-year average of -$46210.5 and a median of -$56000.0 in 2021 define the central range for Change in Account Payables.
  • Biggest YoY gain for Change in Account Payables was 828.46% in 2022; the steepest drop was 5950.0% in 2022.
  • Relay Therapeutics' Change in Account Payables stood at $1.3 million in 2020, then surged by 89.63% to $2.4 million in 2021, then decreased by 19.15% to $2.0 million in 2022, then tumbled by 373.21% to -$5.4 million in 2023, then rose by 19.99% to -$4.3 million in 2024.
  • Per Business Quant, the three most recent readings for RLAY's Change in Account Payables are -$4.3 million (Q3 2024), $3.2 million (Q2 2024), and $102000.0 (Q1 2024).